With the emergence of new ADCs, HER2-low breast cancer, defined as IHC 1 + or IHC 2 + without amplification on ISH, has been recognized as a clinically relevant subgroup and showed a higher therapeutic effect than HER2-zero, which is completely negative (IHC 0) [3–5]. This evidence concerns the gene ERBB2 and breast cancer.